Imaging

Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings. Existing MRI scoring may underserve axSpA in women. Added to therapy differences, a lot to readdress for our female axSpA patients. from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM

Mease et al. Minimal radiographic progression in patients treated with IL-23i guselkumab over 2 years. This trial enriched for high-risk radiographic progression. Clinical response associated with less radiographic progression. @RheumNow #EULAR2022 POS1035 https://t.co/1C21MNVpV8

52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores. Synovial hypertrophy most responsive. Hands and feet, wrist and knees most affected and responsive. @RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa

Deep learning can be used to distinguish seropositive RA from seronegative RA and PsA based on MRI. Early changes in PsO may suggest a PsA-like MRI pattern may be present! Is this how we predict which PsO -> PsA? @RheumNow #EULAR2022 ABST#OP0292 https://t.co/NGfFkSqlaM

There's nothing like a good physical examination Temporal artery exam & ultrasound vs temporal artery biopsy n=97 consecutive ?GCA pts from Carlo Salvarini's group Very decent PPV Those TA exam findings can be hard to find, but they're gold dust. POS0820 #EULAR2022 @RheumNow https://t.co/X9TzIqQBaB

What is "backfill" on MRI? Answer: joint space lesions with a calcified matrix resembling new bone formation found in axSpA. #EULAR2022 POS0149 argues for a standardization of this nomenclature. @RheumNow https://t.co/ifrowQnRcn

To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between contrast/non-contrast imaging in synovitis, less so in tenosynovitis however. https://t.co/xL4XcRlIog@RheumNow https://t.co/0cTep6MHLu

Differentiating AS from OCI using CT scanning by Terrier et al showed that Subchondral Bone Attenuation Coefficient (SBAC) was higher in OCI than AS with a threshold of >7500 Hounslow Units discriminating the two conditions #EULAR2022 @RheumNow POS0126 https://t.co/8MdSe3Dqp7

#EULAR2022 Ultrasound may be used to evaluate patients with RA (POS1393) and SSc (POS1394) 👁️Look for B-lines and pleural irregularity Will require training of MSKUS rheumatologists, but another potential application of US in clinical practice @RheumNow @MymaAlbaydaMD @USSONAR_Rh https://t.co/qtnBviKA3w

Dermatologists doing ultrasound (US) for earlier diagnosis of PsA? Grobelski et al showed in this study of 140 PsA patients, pre-US sensitivity/specifity was 81%/55%, post-US this changed to 62%/91%. Targeted US improved accuracy of referrals for PsA #EULAR2022 @RheumNow OP0029 https://t.co/iajqMuPqcd

Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF

↘️Education level🟰↗️risk of clinical RA in at risk patients. HR=1.8 although partially explained by ↗️ MRI inflammation at Dx. Adjusted on smoking status, age and BMI. Shall we follow this group of patients more closely? OP0035 #EULAR2022 @RheumNow https://t.co/8EJZpaxn3k

Can you train #dermatologists to do ultrasound to detect #PsA if pt has joint pain. POCUS of up to 3 painful joints. US ⬆️derm suspicion of PsA- but this is not feasible in busy offices and no reimbursement @RheumNow #EULAR2022 @eular_org OP0029 https://t.co/9a3gDgIBp0

#EULAR2022 TREAT-EARLIER OP0700 Arthralgia + subclinical inflammation in MRI without RA, treated with MTX + depo steroid injection ▶️In High risk patients, delayed development of synovitis, but does not prevent in long-term ▶️Reduction in disease burden on MTX Rx @RheumNow https://t.co/SKlqMQQTui